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of 16 criteria. Methods: 85 experts were interviewed to estimate the importance 
of each criterion in the decision-making on financing MT for rare diseases. We 
used 10-point scale, where 10 points mean major importance to the priority indica-
tor, and 1point means minor importance. Mean estimates were calculated using 
descriptive statistics, then means were normalized. Results: Respondents were 
41 years on average (ranging from 23 to 64 years), and included 20 public servants, 
16 health administrators, 32 practitioners, and 14 researchers. 44 respondents had 
a scientific degree. The most important criteria were characteristics of treatment - 
“Effect of treatment on quality of life” and “Effect of treatment on life expectancy” 
with 1 points each. The least important criteria were both characteristics of the 
disease - “Cognitive disorders as manifestations of the disease and “Additional bur-
den on the daily lives of care-givers” with 0.28 and 0.1 respectively. ConClusions: 
Characteristics of treatment turned out to be more important for respondents than 
characteristics of disease, therefore characteristics of treatment should be given 
consideration when evaluating rare diseases to determine priority financing.
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PatternS and trendS In OPIOId USe In Iran FrOm 2007 tO 2011
Taheri F.
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objeCtives: Opioid analgesics are proven to be safe and effective in malignant or 
nonmalignant pains. The consumption trend of six opioids (Morphine, Codeine, 
Oxycodone, Fentanyl, Pethidine, and Methadone) in Islamic Republic of Iran 
assumed as an indicator for prescription pattern and is evaluated during five year 
period (2007-2011) as the aim of this study. Methods: The data of opioid analgesic 
consumption were collected from FDO (Food and Drug Organization) of Iran. The 
collected data were converted to DDD (Define Daily Dose) for each of six selected 
opioids in order to be compared accurately. Results: Overall consumption of opi-
oids was grown during the period of investigation. Putting six selected opioids into 
two groups – synthetic and non-synthetic -, the growth rate of synthetic ones are 
obviously higher than those of non-synthetics. Opioid analgesics consumption in 
2011 was shown to be 4 times more than the opioid consumption in 2007. The CAGR 
(Compound Average Growth Rate) between 2007-2011 were reported 111.27%, 33.11%, 
16.48%, 3.91%, 3.76%, and -41.63% for Oxycodone, Methadone, Fentanyl, Morphine, 
Pethidine and Codeine respectively. The growth rate of mentioned above opioids 
for the last year of investigation was reported 41.12%, 16.54%, 29.99%, -0.38%, 7.66%, 
23.67% respectively. ConClusions: Like other low consuming countries, consump-
tion of opioid analgesics in Iran is limited by means of different kinds of barriers. 
There are also parameters which set a specific orientation in opioid consumption. 
Analyzing this trend, results in defining the barriers and other parameters clearly.
PSY101
OrPhan drUg aPPrOvalS In eUrOPe: hIStOrIcal revIew and trendS
Rodrigues J.1, Korchagina D.1, Rémuzat C.1, Brunet J.2, Tavella F.3
1Creativ-Ceutical, Paris, France, 2Assistance Publique des Hôpitaux de Marseille, Marseille, France, 
3Creativ-Ceutical, London, UK
objeCtives: In Europe, orphan designation has been granted by European 
Medicines Agency since 2000. Molecules with orphan designation can benefit from 
a number of incentives to guarantee return on investment for manufacturers. Since 
introduction of orphan legislation, the number of Orphan Drugs (OD) has signifi-
cantly increased. In 2012, total OD sales reached 13% of the whole pharmaceutical 
market. This study aims to analyse current situation and trends in OD approv-
als. Methods: All ODs approved gaining marketing authorization was identified 
through EMA website. Extensions to a new disease were considered as an independ-
ent approval, while extensions of indication for the same condition were not consid-
ered. Information on drug status, indications, therapeutic area, and authorisation 
date was extracted. Results: 77 orphan molecules were identified of which two 
have been withdrawn, and one orphan designation has expired. Yearly approvals 
continuously grow (from 2 ODs approved in 2002 to 12 and 8 drugs in 2012 and 2013 
respectively). By mid-2014, already 6 were approved. There is a high imbalance 
within therapeutic area with 36% for oncology, 27% for endocrine, nutritional and 
metabolic disorders whereas the remaining 37% cover 11 therapeutic classes. No 
product has been approved for 7 therapeutic areas despite existence of rare disor-
ders. Moreover, oncology is associated with the highest growth. ConClusions: 
Orphan drug market is rapidly growing but targeting selective therapeutic areas 
with high potential return on investment. The incentive policies happen to well 
function but discriminate among diseases. A review of orphan drug policies might 
be warranted to ensure patient equity in development of new OD.
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objeCtives: While there exist a number of incentives to stimulate research and 
development of orphan drugs (OD), the Health Technology Assessment (HTA) agen-
cies do not offer specific path for OD in most countries where it is left to payer value 
judgement. This leads to a high inequity in patient access to OD. The study aims 
at comparing the HTA decisions, price and reimbursement level of OD in France 
and Italy. Methods: All OD assessed since 2000 were analysed. Prices, reimburse-
ment rates and decision details were extracted for each drug using Farmadati Italia 
database for Italy and Transparency committee reports, AMELI’s national health 
insurance and Thériaque databases for France. Results: Among 74 OD approved in 
Europe 66 are available in Italy compared to 53 in France. All ODs available in France 
are officially available in Italy. The average delay between the market authorization 
and the price and reimbursement decision was about 16 and 17 months in France 
and Italy, respectively. In France all available drugs are 100% reimbursed through 
hospital, 36 molecules are available in retail pharmacy with reimbursement from 
time, medical/surgical complications to refine a robust measure of effectiveness 
useful to perform cost effectiveness analysis.
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objeCtives: To assess the characteristics of SLE patients currently on Remission 
(Group-1), currently with active disease but not experiencing a flare (Group-2) and 
those who are experiencing flares (Group-3) in Europe (EU). Methods: A multi-
center medical chart review of adult (16-89 yrs) SLE patients was conducted in 
1Q2014 among rheumatologists/internal medicine physicians in UK/France/
Germany/Italy/Spain (5EU). Physicians were recruited from a geographically repre-
sentative sample in each country. Approx. 5 consecutive eligible persistent active or 
relapse remitting SLE patients currently managed as part of usual care were identi-
fied. Physicians abstracted de-identified patient data on disease characteristics, lab 
values and treatment patterns. Patient disease status and humanistic burden was 
assessed by physician per clinical judgment & patient interaction. Results: 747 SLE 
patient charts were abstracted in 5EU (UK: 156/France: 149/Germany: 148/Italy: 146/
Spain: 148); Group-1: 25.7% (range: 19.9% (Italy) –29.7% (Germany)), Group-2: 56.2% 
(range: 42.3% (UK) –66.4% (Italy)), Group-3: 18.1% (range: 13.5 (Germany) –28.8 (UK)). 
Patient characteristics included (Group-1/Group-2/Group-3): age (yrs): 41.4/43/40.6; % 
female: 81.8/80.2/77.8; % full-time employment: 38.0/34.5/32.6; % part-time employ-
ment: 25.5/20.5/17.8; % on sick leave: 3.6/7.6/17.0; % currently receiving treatment 
in in-patient setting: 3.1/7.6/28.1; % hospitalized > = 1 in past-year: 23.4/32.1/55.6. 
Top-5 organ manifestations were (% Group-1/Group-2/Group-3): musculoskeletal: 
90.6/89.5/88.1, mucocutaneous: 86.5/84.0/85.2, haematologic: 45.8/53.8/55.6, renal: 
23.4/26.7/33.3, pulmonary: 15.1/13.6/26.7. In Group-1/Group-2/Group-3, % patients 
with low C3 and C4 were 33.3/53.9/73.4 and 31.6/53.2/77.5 and % anti-ds-DNA posi-
tive were 54.7/71.0/78.5. Humanistic burden (reported via physician ratings, on a 
scale of 0 (most impact) to 7 (least impact)) was (Group-1/Group-2/Group-3, mean 
scores): patient ability to perform every-day tasks: 6.11/5.17/4.37, patient ability to 
interact fully with family and friends: 6.20/5.45/4.90, and patient ability to work/
keep employment: 5.76/4.80/3.87. ConClusions: Over half of the SLE patients had 
an active disease while one-in-five were experiencing a flare in this study cohort, 
with significant variations observed within 5EU. Clinical and humanistic burden 
varied based on patient disease status, with highest burden observed among those 
experiencing flares.
SYStemIc dISOrderS/cOndItIOnS – health care Use & Policy Studies
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objeCtives: Despite increasing policy guidance to encourage the development 
of and access to orphan drugs, the policy landscape indicates a lack of transpar-
ency and consistency across countries. The objective of this study is to compare 
the orphan drug policies of Japan, South Korea, and Taiwan to the policies in the 
EU. Methods: A targeted literature review was conducted to identify papers per-
taining to orphan drugs in Japan, South Korea and Taiwan, with a focus on quantita-
tive analysis for policy-making related to pricing and reimbursement from the payer 
perspective. No limits were placed on language. Country specific policy websites 
were hand-searched. Results: A total of 3465 abstracts were identified for screen-
ing. Of those, 104 were eligible for full-text screening. The definition of prevalence 
with regard to rare diseases in Japan, South Korea and Taiwan was stricter than in 
the EU. All of them had introduced regulations, guidelines and incentives to the 
development of orphan-designated drugs. Strict HTA requirements were waived 
for rare diseases, although cost-effectiveness data are referenced in South Korea. 
In Japan and Taiwan, prices were reduced for existing drugs with new orphan-
designated indications. Within the existing benefits of national health insurance 
schemes or under the coverage of rare disease regulations, full reimbursement 
was given, which is different from the partial reimbursements observed in cer-
tain European countries. In some cases, the application of drug treatment can be 
approved prior to or without market authorisation. The availability of orphan drugs 
to patients was not inferior to that of the EU. ConClusions: While access in Japan, 
South Korea and Taiwan is seemingly no different to the EU, there are no consistent 
or transparent policies in place in these countries. Policy makers should prepare 
innovative schemes that offer warranties to both payers and patients and establish 
a systematic evaluation procedure for manufacturers.
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objeCtives: The ranking and prioritization of rare diseases are crucial in order to 
define for which of them state support measures are justifiable. For this purpose the 
set of 16 criteria to assess rare diseases (8 related to the characteristics of disease, 
and 8 to the characteristics of treatment) was proposed by experts, so multi-criteria 
decision (MCDA) analysis approach could be useful. The aim of the study was to 
assess the reliability of the criteria set and to determine the relative importance 
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Orphan Drugs, only the Eculizumabe for the treatment of PNH has no approved 
registration by the National Health Surveillance Agency (ANVISA). ConClusions: 
Considering its high cost, high judicial demand and limited availability of scientific 
evidence, orphan drugs represent a challenge for researchers and decision makers. 
Clinical benefit, disease severity, availability of therapeutic alternatives, ethical, 
political and social aspects should be considered. It is necessary to start a multi-
disciplinary reflection on the development of HTA models and policies regarding 
rare diseases and innovative treatments in the SUS, as well as fostering the primary 
researches in this field.
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InFlUence hta-baSed recOmmendatIOnS FOr a SamPle OF OrPhan 
drUgS In three cOUntrIeS, and cOUld theSe IndIcate whether OrPhan 
drUgS have a “SPecIal StatUS”?
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Routine HTA methods may not adequately capture all the important considerations 
of a treatment’s value and the impact of the condition on the patient given that 
evidence is often incomplete. This study aims to explore the influence of broader con-
siderations of scientific and social value judgments on reimbursement decisions for 
a sample of orphan drugs.objeCtives: To identify and compare the extent to which 
these broader considerations not captured by the incremental cost-effectiveness ratio 
(ICER) influenced HTA decision-making process in three countries; and, on this basis, 
explore whether orphan drugs have a “special status”. Methods: Countries included 
were England, Scotland and Sweden. Ten drug-indication pairs with EMA orphan des-
ignation and all appraised by NICE were selected. Publicly available HTA reports were 
coded using thematic analysis to systematically identify and compare these broader 
considerations across countries using an existing analytical framework. Results: 
108 different other considerations were identified and grouped into 15 clusters based 
on the information provided. The most common related to the nature of the disease, 
and considerations based on rarity or unmet need. 52% were one of the main reasons 
for the decision, and in some cases, were also a pivotal factor in accepting high and 
uncertain ICERs. Categorising these as social or scientific value judgments was done 
to identify areas where further elicitation of societal preferences, and where more 
consistency and transparency in their use are needed, respectively. Each of these was 
then compared to determine whether they pertained specifically to orphan drug or 
rare disease characteristics. ConClusions: Considerable variation was seen in the 
application of these broader considerations. Identifying these is a way forward to 
highlight areas where more research, or consistency and transparency are needed. 
Some of these other considerations may also favour orphan drugs, furthering the 
debate around whether orphan drugs deserve special status.
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HTA reimbursement recommendations often result in different outcomes across 
countries despite the same evidence being appraised for a same technology. There 
is a need to understand the reasons for these differences. objeCtives: To system-
atically compare HTA processes for a sample of orphan drugs across four countries 
(England, Scotland, Sweden, France): to identify the use and interpretation of the evi-
dence appraised, and highlight differences across countries. Methods: Ten orphan 
drug-indication pairs were selected and systematically compared using a previously 
validated framework. An exploratory sequential mixed methods design divided the 
research into two stages: (1) qualitative in-depth analysis of the decision-making 
processes; and (2) quantitative identification of agency-specific risk preferences 
and agreement levels across countries. Results: Differences at each step of the 
decision-making process were identified. The same pivotal trials were appraised 
but with varying levels of detail in reporting the clinical outcomes, explaining some 
of the reasons for differing HTA recommendations. Agency-specific risk prefer-
ences were identified through correspondence analysis as drivers of these deci-
sions, further explaining some of these differences. Poor to moderate agreement in 
the interpretation of the evidence was measured using Cohen’s kappa scores. This 
reflected situations where the countries interpreted the same evidence differently 
and situations where differences in the handling of the same uncertainties were 
seen, including differences in the extent to which stakeholder input influenced a 
decision. ConClusions: This research systematically compared HTA processes 
in different countries, facilitating the understanding of these complex processes 
including how different HTA bodies conduct value assessments. It enabled to raise 
awareness around the reasons for differences across countries, and highlight 
areas for potential methodological improvements in HTA. Further application of 
this framework to other disease areas and countries is a way forward to improv-
ing the drivers of coverage decisions while better understanding the settings and 
limitations of HTA.
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objeCtives: Orphan drugs are highly priced and top 20 orphan drugs create almost 
2,5% of total drug expenditure in Slovakia. We conducted 8 years review of govern-
ment and literature sources to provide insight into pricing, reimbursement and 
availability situation surrounding top 20 orphan drugs in Slovakia from the health 
care payer perspective. Methods: We provide analysis of official prices, reim-
15% to 100%. In Italy only 9 molecules are reimbursed in retail pharmacy and other 
10 are not reimbursed at all. In 63% cases ex-factory prices in Italy are higher than 
in France. The average price difference in price is 12 % with 50% of products sharing 
almost same price (less than 5% difference). No information is available in France on 
managed entry agreement, while it is publicly available in Italy. This prevents fair 
price comparison. ConClusions: OD are more available in Italy, but reimburse-
ment is poorer than in France. Prices are slightly higher in Italy but France displays 
multiple confidential rebates making it impossible to compare net prices. In Italy 
the actual accessibility depends a lot on regional level unlike France.
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objeCtives: In Italy drug Health Technology Assessment (HTA) is conducted by the 
Scientific Technical Commission of Italian Medicines Agency (AIFA) with further 
negotiation between the manufacturers and the AIFA’s Pricing & Reimbursement 
Committee on price and reimbursement. After the decision is taken it is published 
in the official journal (Gazetta officale), the assessed drug is formally available 
for Italian patients next day. There does not exist a specific procedure for orphan 
drugs (OD), they are evaluated under the same conditions as drugs for common 
diseases. Pharmaco-economic studies are recommended for innovative drugs. The 
objective of the study is to review HTA decisions, prices and reimbursement of OD 
in Italy. Methods: All OD assessed in Italy since 2000 were identified. Prices, reim-
bursement rates and decision details were extracted for each drug using Farmadati 
Italia database. Results: Among 74 OD approved in Europe 66 molecules are offi-
cially available in Italy. It took 5-10 months from granting market authorization to 
final decision on pricing and reimbursement and publication in ‘Gazetta officale’. 
The mean time was about 17 months shorter than for common drugs. Only 9 of 
available molecules are fully reimbursed in Italy, reimbursement of 30 drugs is 
restricted to hospital use, 10 are not reimbursed and 5 are in a special class waiting 
a decision on reimbursement rate. For other drugs information is not available. Post-
marketing surveillance studies were requested for a half of indications, AIFA regis-
tries were reported in 25% of cases. Annual treatment ex-factory price of OD varies 
from € 2 500 to almost € 1 000 000. ConClusions: Almost 90% of approved OD are 
available in Italy. However, the actual situation often differs a lot from the official 
data as some drugs are unavailable from retail or hospital pharmacies. In addition, 
regional authorities contribute to inequity in access especially for “expensive drugs”.
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objeCtives: In France Orphan Drugs (OD) undergo the same Health Technology 
Assessment (HTA) procedure as other drugs. The evaluation is performed by the 
Transparency Committee (TC). Two scores are assigned and further used for pric-
ing & reimbursement decision: drug’s medical benefit (SMR) and improvement in 
medical benefit (ASMR). OD can be eligible to an accelerated procedure established 
for innovative products. The study aim is to analyse HTA decisions, prices and reim-
bursement of OD in France. Methods: Exhaustive prices, reimbursement and HTA 
opinions were extracted using Transparency Committee Website, AMELI’s national 
health insurance and Thériaque databases. Results: Among 74 OD approved 
in Europe, 21 drugs are not available in France. 6 were recently assessed by TC 
but are not yet reimbursed, 14 were not assessed and one got a negative opinion. 
Reimbursement process took between 2 and 5 months after TC opinion. 88% of 
drugs were considered as bringing a substantial medical benefit. At the same time, 
more than a half of medicines were graded as providing a major (9%), significant 
(27%) or moderate (20%) improvement in actual benefit leading to opportunity for 
premium prices, 30% were rated minor improvement, and about 14% no improve-
ment according to TC opinion. Annual treatment prices of OD varie from € 1,500 to 
almost € 1,000,000. ConClusions: About a third of approved ODs are not available 
in France. Most of them were authorized recently and are might become available 
after the HTA and pricing process. In comparison to non OD, the ASMR scoring is 
outstanding. Lack of alternative treatment and severity of the condition appear to 
be the drivers of high SMR-ASMR score.
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objeCtives: In Brazil, the studies produced by members of the Brazilian Network 
for Health Technology Assessment (REBRATS) have contributed in a significant way 
in the process of management and incorporation of technologies in the Brazilian 
Public Health system (SUS). However, there is still a lack of a Pharmaceutical 
Assistance and HTA Policy for rare diseases and the evidence for orphan drugs are 
limited and lower. The coverage for these drugs, is frequently done through judicial 
orders, political and social pressure, with no support of evidence-based medicine. 
The objectives is to evaluate the production of HTA studies for orphan drugs made 
by REBRATS members. Methods: Query to the REBRATS database and the internal 
production of the HTA coordination, prioritizing 6 major diseases: Gaucher dis-
ease, Fabry disease, Mucopolysaccharidosis Type I (MPS I); Mucopolysaccharidosis 
Type II (MPS II); Mucopolysaccharidosis Type VI (MPS VI); Paroxysmal Nocturnal 
Haemoglobinuria (PNH). Results: Five HTA studies were found, which are: a 
Rapid Response for Gaucher disease; a study on Health Technology Management 
for Fabry disease; an Economic Evaluation for MPS I, II and VI; a Systematic Review 
for Mucopolysaccharidosis Type II; and one Rapid Review for PNH. For the evaluated 
